Lilly and Regeneron's EUA for their COVID-19 MAb therapies short of clinically relevant data, say analysts
As US President Donald Trump puts his weight behind Eli Lilly (NYSE: LLY) and Regeneron Pharmaceuticals’ (Nasdaq: REGN) bid for US Food and Drug Administration Emergency Use Authorization (EUA) for their respective COVID-19 monoclonal antibody (MAb) therapies, pharma writers for the investigative team at GlobalData assess the situation.
“Experts we interviewed emphasized the need for more clinically relevant data for a higher guarantee of a successful EUA,” Manasi Vaidya explained. “Lilly is aiming for its LY-CoV555 monotherapy to win an EUA, while Regeneron’s bid involves its antibody cocktail, REGN-COV2 consisting of REGN10933 and REGN10987, she added.
Fellow writer Reynald Castañeda said: “Despite both MAb therapies showing they can reduce SARS-CoV-2 viral load in non-hospitalized COVID-19 patients, larger prospective datasets on endpoints such as reduced hospitalization and emergency room visits are needed for stronger EUA potential. Available data only offers a slight efficacy signal on these clinically important measures.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze